SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Aberrant CpG island methylation is a hallmark of oncogenesis, but its inhibitory mechanisms remain poorly understood.
• DNA methyltransferase 3 alpha (DNMT3A) plays a critical role in de novo DNA methylation, contributing to aberrant methylation patterns in cancer.

Purpose of the Study:

• To identify novel inhibitory factors of DNMT3A and elucidate their role in oncogenesis.
• To investigate the function of sal-like 3 (SALL3) as a potential regulator of DNMT3A activity and CpG island methylation.

Main Methods:

• Co-immunoprecipitation and in vitro binding assays to confirm direct interaction between SALL3 and DNMT3A.
• Cell culture experiments assessing DNMT3A activity and CpG island methylation levels upon SALL3 modulation (expression or depletion).
• Chromatin immunoprecipitation to evaluate the effect of SALL3 on DNMT3A binding to chromatin.

Main Results:

• SALL3 directly interacts with DNMT3A via its double zinc finger motif and the DNMT3A PWWP domain.
• SALL3 expression inhibits DNMT3A-mediated CpG island methylation in vitro and in cell culture.
• SALL3 depletion enhances CpG island methylation and DNMT3A methyltransferase activity.
• SALL3 expression reduces DNMT3A chromatin binding, while SALL3 depletion increases it.
• SALL3 is inducible by BMP-4 and epigenetically silenced in hepatocellular carcinoma (HCC).

Conclusions:

• SALL3 acts as a novel endogenous inhibitor of DNMT3A, regulating its activity and chromatin binding.
• Silencing of SALL3 contributes to accelerated DNA methylation in HCC, suggesting a role in tumorigenesis.
• Understanding SALL3's inhibitory function provides insights into DNMT3A regulation and potential therapeutic strategies against aberrant methylation in cancer.